<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04514731</url>
  </required_header>
  <id_info>
    <org_study_id>B-2008/631-002</org_study_id>
    <nct_id>NCT04514731</nct_id>
  </id_info>
  <brief_title>Magnesium Sulfate and Neuroendocrine Hormone</brief_title>
  <official_title>Neuroendocrine Changes Associated With Magnesium Sulfate Administration in Surgical Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Total knee arthroplasty is a procedure that relieves pain in patients with severe symptomatic&#xD;
      osteoarthritis, but it can be associated with postoperative pain, which hinders recovery. In&#xD;
      the previous study, we reported evidence of increased pain in patients undergoing staged&#xD;
      total knee arthroplasty, in whom the second operated knee had greater sensitivity (tertiary&#xD;
      hyperalgesia) as a result of the surgical injury to the first operated knee.&#xD;
&#xD;
      Magnesium sulfate is an effective analgesic adjuvant for postoperative pain. Its analgesic&#xD;
      property seems to be associated with the regulation of calcium influx into the cells, or&#xD;
      antagonism of N-methyl-D-aspartate receptors in the central nervous system. Additionally,&#xD;
      magnesium is known to have an anti-inflammatory effect. Inflammatory state may accompany with&#xD;
      pain via peripheral or central sensitization.&#xD;
&#xD;
      Recently, we reported that magnesium sulfate effectively attenuates not only postoperative&#xD;
      pain but also increased pain intensity without serious adverse effects in the bilateral&#xD;
      staged total knee arthroplasty. However, the exact mechanism regarding these effects of&#xD;
      magnesium sulfate remains unclear.&#xD;
&#xD;
      In the present study, we will investigate the analgesic mechanism of magnesium sulfate via&#xD;
      analysis of endocrine neurosteroid levels in patients undergoing bilateral staged total knee&#xD;
      arthroplasty.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 21, 2021</start_date>
  <completion_date type="Anticipated">December 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The profiles of cortisol in the saliva</measure>
    <time_frame>From the evening (21:00) before the operation day to the morning (60 minutes after wake-up) of the operation day, for each stage of the operation</time_frame>
    <description>The cortisol concentrations in the saliva, at the evening before the operation (21:00~22:00), just after wake-up in the morning of the operation day, and 30 and 60 minutes after wake-up</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The profiles of dehydroepiandrosterone (DHEA) in the saliva</measure>
    <time_frame>From the evening (21:00) before the operation day to the morning (60 minutes after wake-up) of the operation day, for each stage of the operation</time_frame>
    <description>The DHEA concentrations in the saliva, at the evening before the operation (21:00~22:00), just after wake-up in the morning of the operation day, and 30 and 60 minutes after wake-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative pain</measure>
    <time_frame>Postoperative 24 hour</time_frame>
    <description>Numerical rating scale pain score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative pain</measure>
    <time_frame>Postoperative 48 hour</time_frame>
    <description>Numerical rating scale pain score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient controlled analgesia (PCA)</measure>
    <time_frame>Postoperative 24 hour</time_frame>
    <description>Amounts of PCA consumption</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient controlled analgesia (PCA)</measure>
    <time_frame>Postoperative 48 hour</time_frame>
    <description>Amounts of PCA consumption</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nausea</measure>
    <time_frame>Postoperative 24 hour</time_frame>
    <description>Incidence of nausea</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nausea</measure>
    <time_frame>Postoperative 48 hour</time_frame>
    <description>Incidence of nausea</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vomiting</measure>
    <time_frame>Postoperative 24 hour</time_frame>
    <description>Incidence of vomiting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vomiting</measure>
    <time_frame>Postoperative 48 hour</time_frame>
    <description>Incidence of vomiting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-emetics</measure>
    <time_frame>Postoperative 24 hour</time_frame>
    <description>Amounts of anti-emetics consumption</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-emetics</measure>
    <time_frame>Postoperative 48 hour</time_frame>
    <description>Amounts of anti-emetics consumption</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Arthropathy of Knee</condition>
  <condition>Magnesium Sulfate</condition>
  <condition>Cortisol</condition>
  <condition>Dehydroepiandrosterone</condition>
  <arm_group>
    <arm_group_label>Group M</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the magnesium sulfate group received magnesium sulfate 50 mg/kg for 15 minutes after spinal anesthesia and then 15 mg/kg/hour by continuous intravenous infusion until the end of surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group S</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients in the saline group received the same volume of isotonic saline over the same period with magnesium infusion protocol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnesium sulfate</intervention_name>
    <description>Magnesium group receives magnesium sulfate (50 mg/kg) in 100 mL of isotonic saline over 15 minutes after spinal anesthesia, followed by a continuous magnesium sulfate infusion (15 mg/kg/hour) until the end of surgery.</description>
    <arm_group_label>Group M</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isotonic Saline</intervention_name>
    <description>Isotonic saline group receives the same volume of isotonic saline, administered according to the same methods as in the magnesium group.</description>
    <arm_group_label>Group S</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who undergo staged bilateral total knee arthroplasty&#xD;
&#xD;
          -  Spinal anesthesia&#xD;
&#xD;
          -  American Society of Anesthesiologists physical status 1 and 2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who undergo unilateral total knee arthroplasty&#xD;
&#xD;
          -  General anesthesia&#xD;
&#xD;
          -  Musculoskeletal disease&#xD;
&#xD;
          -  Hypermagnesemia&#xD;
&#xD;
          -  Atrioventricular block&#xD;
&#xD;
          -  Previous history of administration of calcium channel blockers&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyun-Jung Shin, MD., PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Bundang Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hyun-Jung Shin, MD., PhD.</last_name>
    <phone>0317877508</phone>
    <email>hjshin.anesth@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyun-Jung Shin, Ph.D., M.D.</last_name>
      <phone>82317877499</phone>
      <email>hjshin.anesth@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 13, 2020</study_first_submitted>
  <study_first_submitted_qc>August 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2020</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Hyun-Jung Shin</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Joint Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Magnesium Sulfate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

